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Abstract
Background: The 2009 revised World Health Organization (WHO) guidelines for dengue describe fever as the core
symptom. Accordingly, the diagnosis of non-febrile patients is complicated. The aim of this study was to evaluate
the importance of fever in patients with dengue according to the 2009 revised WHO classification.
Methods: In this study, we assessed 30,670 dengue cases using enzyme-linked immunosorbent assay, detection of
the non-structural protein 1, or polymerase chain reaction for diagnostic confirmation. Fisher’s exact test was used
to evaluate associations between fever and related clinical manifestations. The Mann–Whitney U test was used to
assess the association of dengue classification with fever and time to treatment. The effects of fever and time to
treatment on the risk of progression were analyzed using an ordinal logistic regression to stereotype the model.
Results: Disease classification was found to associate significantly with both fever and time to treatment (both
P < 0.001). Non-febrile patients were nearly four-fold more likely to exhibit “dengue without warning signs”
than “severe dengue” (odds ratio [OR] = 3.74; 95% confidence interval [CI]: 3.20–4.36). Patients who received
treatment within 7 days were twice as likely to have “dengue without warning signs” as opposed
to “severe dengue” when compared to those who waited >7 days (OR = 2.23; 95% CI: 1.78–2.80). However,
this difference was negligible in the multivariate analysis (OR = 1.02; 95% CI: 0.98–1.07).
Conclusions: Fever is a risk factor for disease progression in patients with dengue. However, non-febrile
patients should not be neglected because this may delay treatment and could lead to more severe disease.
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Background
Dengue is an infectious disease that exhibits acute evolu-
tion [1]. The incidence of dengue has increased across
all age groups [2] to become a clear public health prob-
lem [3]. The causative dengue virus (DENV) belongs to
the Flaviviridae family within the Flavivirus genus [4],
and harbors RNA genetic material that encodes three
structural (capsid [C], membrane protein [M] and glyco-
protein for the viral envelope [E]) and seven non-
structural (NS1, NS2a, NS2b, NS3, NS4a, NS4b and
NS5) proteins [5] essential for viral replication in host
cells [4, 6]. DENV is transmitted by a bite from a female
Aedes aegypti mosquito [7] that caries one of the four
virus serotypes [4]. The viremic period of the disease is
defined as the period during which dengue virus can be
detected in the blood of an infected human [6]. Follow-
ing inoculation of the virus into the host, the incubation
period may vary from 4 to 10 days [8, 9], after which
various clinical signs and symptoms will emerge [9]. In-
fection with a specific virus serotype initiates permanent,
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or homotypic, immunity against that serotype [5, 6, 9].
Reinfection with a different strain may induce a cross-
reaction in which existing antibodies from the first infection
bind but do not abolish the virus; this process generally
leads to more severe disease [5, 10].
The 1997 World Health Organization (WHO) guide-
lines on dengue presented three disease categories: den-
gue fever, dengue hemorrhagic fever, and dengue shock
syndrome [3]. Investigations intended to classify the dis-
ease and facilitate the initiation of treatment are neces-
sary when a patient is suspected to have dengue.
Patients with dengue fever usually presents with an
abrupt-onset high fever [11] and two or more other
symptoms, such as headache, retro-orbital pain, myalgia,
and arthralgia. Laboratory tests may indicate leukopenia
and thrombocytopenia without plasma leakage. In
addition to the classic symptoms of dengue fever, pa-
tients with dengue hemorrhagic fever present with a
positive result on the tourniquet test and signs of spon-
taneous bleeding. This disease is divided into four
grades, of which grades three and four are defined as
dengue shock syndrome, indicated by the presence of
signs of circulatory deficiency such as a weak pulse and
hypotension, or even an absent pulse and blood pres-
sure, as a result of plasma leakage [8].
Owing to difficulties with the application of this classi-
fication to patients with more severe symptoms, the
WHO revised its guidelines in 2009 to include three cat-
egories: dengue without warning signs, dengue with
warning signs, and severe dengue [2, 3, 12]. Symptoms
of dengue with warning signs may include abdominal pain,
vomiting, fluid retention, bleeding from mucous mem-
branes, lethargy, and hepatomegaly. Laboratory tests may
indicate an increase in erythrocytes with thrombocytopenia.
Patients with severe dengue experience plasma leakage,
bleeding, and organ failure [2, 3, 8]. Notably, fever is the
core symptom of both classifications. Patients who do not
present with fever or who develop fever later are difficult to
classify according to these guidelines. Furthermore, dengue
may present with symptoms similar to other acute fe-
brile illnesses, especially those caused by other arbovi-
ruses such as the Zika and Chikungunya viruses, which
were both recently detected in Brazil (in 2015 and 2014,
respectively), thus contributing to the complicated diagno-
sis of dengue [13].
The main objective of the present study was to evalu-
ate the importance of fever in patients with dengue, to
analyze clinical data related to fever, and to assess asso-
ciations between fever and the severity indices listed in
the 2009 revised WHO guidelines.
Methods
This study evaluated 30,670 confirmed cases of dengue
identified in São José do Rio Preto, São Paulo, Brazil
between April 1998 and June 2012 (before the emer-
gence of the Zika and Chikungunya viruses in Brazil).
Patient information was collected from medical forms of
the dengue surveillance system (SINAN, Information
System for Notifiable Diseases) associated with the Bra-
zilian Ministry of Health (Additional file 1). This service
requires notification of all suspected cases of this disease
nationwide. Diagnostic confirmation was conducted in
government laboratories via the enzyme-linked immuno-
sorbent assay (ELISA)-based detection of specific IgM
antibodies, detection of the non-structural protein 1
(NS1), or polymerase chain reaction (PCR).
The classification system proposed in the WHO 2009
guidelines was used as an ordinal dependent variable.
The outcome was one of three different classification
levels: dengue without warning signs, dengue with warn-
ing signs, and severe dengue. The presence of fever re-
ported by the patient or measured at the time of medical
examination was evaluated separately as an independent
variable. The time to treatment from the onset of any
dengue symptom was categorized as ≤7 days or >7 days
and also analyzed as an independent variable. General
clinical manifestations, such as headache, vomiting, arth-
ralgia, myalgia, prostration, and diarrhea, were grouped
as a single variable (general symptoms). Hemorrhagic
manifestations were also included as an independent
variable and included the clinical presentation of epistaxis,
petechiae, rash, gingival bleeding, hematuria, gastrointes-
tinal bleeding, menorrhagia, and positive tourniquet test.
Ascites, pleural effusion, pericardial effusion, hematocrit
elevation above the reference levels for sex and age, and
the presence of hypoproteinemia were grouped as a plasma
leakage variable. Organ failure, including myocarditis,
neurological manifestations (as impaired consciousness),
and liver failure (AST or ALT > =1000 IU/mL), as defined
by WHO, were considered another variable [8]. All sus-
pected cases of dengue which are notified to the Brazilian
Ministry of Health are previously evaluated by a doctor or
nurse. In our study we do not consider whether the patient
was or was not referred to a hospital for both febrile cases
as non-febrile.
Fisher’s exact test was used to assess the associations
of fever with sex, general symptoms, hemorrhagic mani-
festations, plasma leakage, organ failure, and time to
treatment. The Mann–Whitney U test was used to verify
associations of the WHO 2009 classification for dengue
with fever and the time to treatment. An ordinal logistic
regression to stereotype model was used to analyze the
risk of progression to different levels in the WHO 2009
classification among patients with or without fever. Se-
vere dengue was used as the reference category in the
pairwise comparison for each classification. The time
interval from symptom onset to presentation for medical
care was also analyzed. Odds ratios (ORs) were defined
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as the ratio of the likelihood of dengue without warning
signs or severe dengue in the first comparison and of the
likelihood of dengue with warning signs or severe den-
gue in the second comparison. The quality-of-fit of the
models was assessed using the deviance test. All statis-
tical tests were performed using SPSS (version 19; SPSS,
Inc., Chicago, IL, USA) and the free statistical program
R (version 3.2.0, VGAM package rrvglm function; The R
Project for Statistical Computing, Vienna, Austria), and
a 5% significance level was implemented.
This study was authorized by the Ethical Committee
of the União das Faculdades dos Grandes Lagos, São
José do Rio Preto, São Paulo, Brazil. The requirement
for informed patient consent was waived.
Results
Of the 30,670 patients with dengue recorded during the
study period, fever information was not recorded in the
medical forms to 15,914 patients; however, in 14,756
forms this information was present properly. Of these,
14.248 (96.6%) had fever and 508 (3.4%) had not. Only
patients with adequate record about the occurrence of
were evaluated statistically. 11,726 (79.5%) were aged be-
tween 15 and 60 years; 1702 (11.5%) were older than
60 years, and 1328 (9.0%) were aged 0–14 years. The
study included 8711 (59.0%) female and 5996 (40.6%)
male patients (information on sex was not available for
49 (0.3%) individuals).
Information about general symptoms was available for
all 14,756 individuals. Of these, 14,717 (99.7%) exhibited
general symptoms, whereas 39 (0.3%) patients reported
no general complaints. Of the 14,744 patients with avali-
able information about hemorrhagic manifestations,
9320 (63.2%) presented with at least one hemorrhagic
manifestation, whereas 5424 (36.8%) had no bleeding
complaints patients (information on hemorrhagic mani-
festation was not available for 12 (0.1%) individuals). At
least one form of plasma extravasation was reported in
427 (2.9%) patients, whereas 12,417 (84.1%) had no re-
lated complaints (information on plasma extravasation
was not available for 1912 (13.0%) individuals). There
were 5041 (34.2%) reports of organ dysfunction, whereas
8920 (60.4%) had no dysfunction complaints reported.
Regarding the revised WHO classification, 1499 (10.2%),
12,889 (87.3%), and 368 (2.5%) patients were diagnosed
with dengue without warning signs, dengue with warn-
ing signs, and severe dengue, respectively. The average
time to treatment was 5.84 days (standard deviation,
5.25 days).
There was a significantly higher incidence of fever
among women (n = 8348, 58.8%) vs. men (n = 5854,
41.2%; P < 0.001). Fever was also associated with an in-
creased incidence of general symptoms (P < 0.001). In
contrast, fever was not statistically significantly associ-
ated with hemorrhagic manifestations (P = 0.261) or
plasma leakage (P = 0.689). Despite a significant associ-
ation of fever with organ failure (P = 0.011) 150 patients
who did not present with fever were diagnosed with fail-
ure of at least one of the studied organs. Fever was not
statistically significantly associated with the time to
treatment (P = 0.133; Table 1).
The Mann–Whitney test indicated a statistically signifi-
cant association between fever and the WHO classifica-
tion (U = 3,160,348.5; P < 0.001). A significant association
was also observed between the time to treatment and
WHO classification (U = 43,705,568.5; P < 0.001). The or-
dinal logistic regression was adjusted using the stereotype
model, and weights were estimated as model parameters.
The univariate analysis indicated that the significant asso-
ciation detected by the Mann–Whitney test represented
an increased likelihood that non-febrile individuals would
present with “dengue without warning signs” rather than
“severe dengue”; this likelihood was nearly four-fold
higher than that of febrile individuals (OR = 3.73; 95%
confidence interval [CI]: 3 19–4.36). In contrast, the likeli-
hood that patients with or without fever would present
with “dengue with warning signs” or “severe dengue” was
similar (OR = 1.04; 95% CI: 0.89–1.21).
Patients who presented for treatment within 7 days of
symptom onset were twice as likely to be classified as
having “dengue without warning signs” rather than “se-
vere dengue”, compared to those who presented for
treatment more than 7 days after symptom onset. When
these two variables were evaluated in the same
































5,854 (41.2) 8,348 (58.8) 13,960 (100.0) 0 (0) 8987 (63.1) 5250 (36.9) 411 (3.3) 11,985 (96.7) 4,891 (36.3) 8,581 (63.7) 11,132 (78.7) 3,008 (21.3)
No
142 (28.1) 363 (71.9) 469 (92.3) 39 (7.7) 333 (65.7) 174 (34.3) 16 (3.6) 432 (96.4) 150 (30.7) 339 (69.3) 380 (75.8) 121 (3.9)
Fisher’s exact test: *P < 0.001, **P = 0.261, †P = 0.689, ††P = 0.011, ‡P = 0.133
Tukasan et al. BMC Infectious Diseases  (2017) 17:6 Page 3 of 6
multivariate analysis model, the magnitude of the associ-
ation between patients without fever who presented with
“dengue without warning signs” vs. “severe dengue” was
retained (OR = 3.74; 95% CI: 3.20–4.36). However, the
difference between patients who received treatment
within 7 days or >7 days of symptom onset was negli-
gible (OR = 1.02; 95% CI: 0.98–1.07) when “dengue
without warning signs” and “severe dengue” were con-
sidered. All models exhibited good fit in the deviance
test (P > 0.05; Table 2).
Discussion
Previous literature reports have not utilized such a large
number of patients with both clinically and laboratory
confirmed dengue nor a stereotype model to evaluate
the importance of fever as a trigger for the investigation
of suspected dengue cases. Furthermore, the present
study is the first to use the 2009 revised WHO classifica-
tion system as an outcome measure. Although the re-
sults demonstrated a statistically significant association
between fever and organ failure (P = 0.011), 150 patients
without fever also experienced organ failure. Both uni-
variate and multivariate logistic regression analyses indi-
cated that patients without fever were less likely to have
severe disease (OR = 3.73; 95% CI: 3.19–4.36 and OR =
3.74; 95% CI: 3.20–4.36, respectively). Furthermore, in
the univariate analysis, patients who received treatment
within 7 days were less likely to have severe disease
when compared to those who received a delayed diagno-
sis and treatment (OR = 2.23; 95% CI: 1.78–2.80); how-
ever, this difference was negligible in the multivariate
analysis (OR = 1.02; 95% CI: 0.98–1.07).
The presence of fever, as well as the tourniquet test
[11], in suspected dengue carriers is often highly valued
as a method of defining the continuity of the conducting
case. Even the 2009 WHO guidelines emphasize the
presence of fever as a starting point for dengue evalu-
ation [8, 14]. However, the absence of fever, observed in
508 of our study participants, might reduce the demand
for medical care. We note that our results highlight the
fact that patients without fever were more likely to re-
main in the lower strata of the 2009 revised classifica-
tion, and therefore those with fever presented with more
severe cases of dengue [8, 11, 14].
Generally, fever has been present in most [15–17], if
not all, patients participating in studies of dengue [18];
however, a lack of fever in patients with dengue might
be an obstacle to the initiation of investigations and the
classification of arbovirosis as dengue without warning
signs, dengue with warning signs, or severe dengue.
Fever might not be important in the detection of den-
gue, as shown by Ho et al. in a 2013 study of 581 pa-
tients from a hospital in Taiwan in which fever was
found to have a moderate sensitivity (67.3%) and positive
predictive value (71.7%) and a low specificity (12.3%)
and negative predictive value (10.2%) [19]. Reliance on
the presentation of fever for a dengue diagnosis might
lead to delayed treatment and an increase in disease se-
verity. Furthermore, in a study conducted in the State
of Minas Gerais, Brazil, 5.1% of patients with dengue
who were admitted to an intensive care unit had not
presented with fever at any time prior to admission
[20]. Additionally, asymptomatic or presymptomatic in-
dividuals might present a high risk of DENV transmis-
sion to mosquitos (OR = 5.10; CI: 1.76–57.51 and OR =
4.84; CI: 2:02–11:58, respectively) [21].
Detection of the Chikungunya and Zika viruses in
Brazil in 2014 [22] and 2015 [13], respectively, has com-
plicated the diagnosis of dengue based on the presence
of fever because infections with these arboviruses yield
similar clinical presentations [13]. In addition, cases of
Zika might also present clinically as afebrile, as described
in a study by Yap [23], leading to the misdiagnosis of
dengue as Zika and possibly delaying the initiation of
appropriate treatment, leading to further clinical compli-
cations. In our cohort of patients with dengue, delays in
presentation for treatment were associated with a worse
prognosis. Similar results were also found in another
study that used a threshold of 4 days with regard to
presentation for treatment [19, 24].
We note that we have implemented all precautions to
eliminate potential errors that are common in very large
retrospective databases, particularly with regard to the
Table 2 Ordinal logistic regression (stereotype model)a
Dengue without warning
signs vs. severe dengue













No 1.31 3.73 3.19–4.36 0.04 1.04 0.89–1.21
Time to treatment
> 7 daysb 1.00 1.00




No 1.32 3.74 3.20–4.36 0.04 1.04 0.89–1.22
Time to treatment
> 7 daysb 1.00 1.00
≤ 7 days 0.02 1.02 0.98–1.07 0.0006 1.00 0.96–1.04
Deviance test: P > 0.05 for all models
aDependent variable: 2009 World Health Organization guideline
dengue classification
bReference
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annotation of patient records. Additionally, we believe
that correct and exhaustive debugging of our data, which
involved the removal of conflicting information, in-
creased the reliability of our obtained results and mini-
mized the limitations associated with this type of study.
Conclusions
We conclude that the presence of fever in patients with
dengue can be a risk factor for progression to more se-
vere disease. However, patients who do not present with
fever should not be neglected, as this might delay treat-
ment, another factor associated with the development of
severe disease.
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